KRON: Utang jangka cendhak marang ekuitas Kronos Bio Inc

The business resilience of Kronos Bio, Inc. (KRON) is constrained by a lack of profitability and massive R&D expenditures, as confirmed by this chart showing a market valuation of 0.01. Kronos Bio, Inc. (KRON) develops cancer treatment methods by targeting cellular transcription factors. To outpace competitors in the race for market share, the firm continuously raises capital to conduct clinical trials.

This indicator measures the proportion of liabilities maturing within one year relative to equity, allowing for an assessment of liquidity risk and short-term financial stability. By analyzing changes in the short-term debt-to-equity ratio, an investor can evaluate the ability of Kronos Bio, Inc. (KRON) management to effectively contain intensive cash burn while developing costly oncology drugs.